GP Pharm: Press Releases
GP Pharm to Exhibit at CPhI 2011
For the eighth consecutive year GP Pharm will be present at CPhI, the world's most important pharma event, from 25-27 October this year. This year the exhibition takes place in Frankfurt...
GP Pharm Expands its Pharmaceutical Line Against Advanced Colorectal Cancer with Oxaliplatin and Irinotecan 300mg and 500mg
GP Pharm has started the commercialisation of Oxaliplatin and Irinotecan 300mg and 500mg, drugs to treat metastatic colorectal cancer. Oxaliplatin 50mg and 100mg is a stereoisomer in...
GP Pharm Obtains Approval for GCC Countries
Last January, GCC-DR (Gulf Central Committee for Drug Registration) granted a Registration Certificate of Manufacturing Site to GP Pharm. This certificate is valid for the next five...
PHOENIX Study Proposes Integration Measures Between the Financial World and Biotechnological Companies
CataloniaBIO has launched the PHOENIX Study to get the financial world's vision about the sector and the financial needs of biotech companies. The study was presented on 7 July at the...
GP Pharm Named as One of the Most Innovative Pharmaceutical Companies in Spain for the Second Consecutive Year
GP Pharm, a pioneer in the development of controlled drug release, has been granted for the second consecutive year, the rating of 'very good' in the Plan Proforma. The certification awarded...
GP Pharm Looks Back on Another Successful Year at the euroPLX46
GP Pharm has successfully participated again in the 46th euroPLX edition that took place in Vienna, on 30 and 31 May 2011. The main objective of GP Pharm during the event was to announce...
GP Pharm to Begin Phase III Clinical Trial of Lutrate® Three Months for the Treatment of Advanced Prostate Cancer
GP Pharm, a pioneer in the development of drug delivery systems, will start the phase III clinical trial of three months Lutrate®, a formulation of a quarterly dose of Leuprolide based...
GP Pharm Enjoys Another Successful Year at the BioPartnering North America 2011 (BPN)
GP Pharm took part in the BioPartnering North America 2011 (BPN) celebrated in Vancouver (Canada) from 28 February to 1 March. Over 800 delegates, from 500 companies and 27 countries,...
GP Pharm Uploads Details of its Urology, Oncology, CNS and CVS Injectable Products
GP Pharm is the pharmaceutical branch of the Lipotec Group, based in Barcelona, Spain. GP Pharm specialises in the research, development, production and marketing of injectable products within...
GP Pharm Files Lutrate Depot® One Month for Registration in Five European Countries
The Spanish biotech company GP Pharm, which pioneers and develops controlled release systems for injection, has filed the Lutrate Depot® 1 month (Leuprolide acetate 3.75mg) dossier...
GP Pharm Concludes Final Reports for Preclinical Studies Of Sarcodoxome®
Final reports for preclinical studies for GP Pharm’s Liposomal Doxorubicine Sarcodoxome® have been released. Those studies are related to one of the major safety improvements of GP...
New Product Registration at GP Pharm
In November GP Pharm has obtained in Spain the approval for the Octreotide as generic product in four different presentations. (50mg/mL, 100mg/mL and 500mg/mL in ampoules, and 200mg...
GP Pharm's Participation at Euro-Regional Meetings of Biotech and Healthcare
Last December 3rd and 4th 2007 GP Pharm participate at the event Euroregional meetings for Biotechnology and Healthcare taking place at Toulouse (France). During this event GP Pharm had...
Twitter